Annovis Bio, Inc. 8-K

What Happened

• On March 16, 2026, Annovis Bio, Inc. announced it reported earnings for the year ended December 31, 2025 and furnished a press release with those results as Exhibit 99 to its Form 8‑K. The 8‑K (Item 2.02) states the press release is incorporated by reference into the filing.

Key Details

• Filing date: March 16, 2026 (Form 8‑K).
• Period reported: year ended December 31, 2025 (earnings/results).
• The press release containing the results is furnished as Exhibit 99 to the 8‑K.
• The filing also includes an Inline XBRL cover page interactive data file (Exhibit 104).

Why It Matters

• This 8‑K notifies investors that Annovis has publicly released its annual financial results; those results (revenue, net income/loss, cash position, and other metrics) will be in the press release (Exhibit 99) rather than in the body of the 8‑K itself. Retail investors should review the Exhibit 99 press release and any subsequent SEC filings for the specific financial figures and management commentary to assess impact on valuation and near‑term outlook.